Navigation Links
BioLineRx Announces New Positive Results in Phase 2a trial for Orally Available Inflammatory Bowel Disease Treatment
Date:11/26/2013

JERUSALEM, Nov. 26, 2013 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX)(TASE:BLRX), a biopharmaceutical development company, announced today additional Phase 2a results showing significant improvement of disease measurements in biopsies taken from inflammatory bowel disease (IBD) patients treated with BL-7040, an orally available drug for treating IBD. The histological and biochemical analyses of inflammation indicators reinforce the initial positive results of the study, reported in April 2013, which showed that BL-7040 is safe and effective in treating ulcerative colitis, a form of IBD.

(Logo:  http://photos.prnewswire.com/prnh/20130730/630769)

In order to perform the histological and biochemical analyses, biopsies were taken from trial participants before and after treatment. Biopsies from each time point were collected and randomly assigned to either a histological evaluation or to an assessment for levels of cytokines, considered as pro-inflammatory bio-markers. All analyses were performed in a blinded manner.

The histological results show that neutrophil levels were significantly reduced (p=0.002) in patients treated with BL-7040. Neutrophils are the major cellular participant in acute inflammation, and their presence in the colon mucosa is believed to play a key role in causing tissue damage and clinical symptoms in IBD patients. Neutrophil levels are known to decrease when a patient's clinical condition improves. In this respect, all patients whose neutrophil levels were reduced also showed a clinical improvement as assessed by their Mayo score, the gold standard for assessing ulcerative colitis therapy.

An additional measure of disease severity is the level of the pro-inflammatory cytokine, interleukin 6 (IL-6). IL-6 is the predominant cytokine found in inflamed areas in ulcerative colitis patients, and its concentra
'/>"/>

SOURCE BioLineRx
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. BioLineRx Reports Publication in Peer Review Journal of Positive Phase 1/2 Results in Stem Cell Mobilization for Multiple Myeloma
2. BioLineRx Reports Third Quarter 2013 Financial Results
3. BioLineRx to Report Third Quarter 2013 Results on November 13, 2013
4. BioLineRx to Hold Analyst and Investor Day in New York on November 21, 2013
5. BioLineRx Receives Regulatory Approval to Commence Phase 1/2 Trial for Novel Treatment of Celiac Disease
6. BioLineRx Announces In-Licensing of BL-9020, for Treatment of Type 1 Diabetes
7. BioLineRx Announces Regulatory Submission for Phase 1/2 Trial for Novel Treatment of Celiac Disease
8. BioLineRx Announces Receipt of a Notice of Allowance from USPTO for Patent on Use of BL-8020, an Oral, Interferon-Free Treatment for Hepatitis C
9. BioLineRx To Present At 15th Annual Rodman & Renshaw Global Investment Conference In New York
10. BioLineRx Announces Issuance of United States Patent Covering Use of BL-8040 for Obtaining Stem Cells
11. BioLineRx to Present at 15th International Celiac Disease Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... , July 30, 2014 Stryker brand ambassadors ... week at the 3M Championship Champions Tour event near ... in Blaine . Stryker is the official joint ... Starting Friday, August 1 st through Sunday, August ... Mobility Zone; an on-site joint health destination located in the Pioneer ...
(Date:7/30/2014)... , July 30, 2014 Silicon Valley Bank, ... a study today that examines the merger, acquisition ... device companies.  According to the annual report based on ... potential returns since SVB started tracking the data in ... IPO.  Built on solid healthcare M&A activity over the ...
(Date:7/30/2014)... YORK , July 30, 2014 ACCESS ... for oncology supportive care, announced that its novel product ... in an article on OncLive.com titled, "Study Finds Mouth ... Cancers."  Dr. Steve Sonis , a leading expert ... seen in the oncology community for evidence-based strategies for ...
Breaking Medicine Technology:Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 2Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 3Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 4Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 5Report: Biopharma and Medical Device Companies Beat Historic Investment Returns 2Report: Biopharma and Medical Device Companies Beat Historic Investment Returns 3Access Pharmaceuticals Featured On OncLive.com 2Access Pharmaceuticals Featured On OncLive.com 3
... the global leader in technology support and BPO services ... today the opening of its new Global Operations Center ... city of Dalian, will specialize in providing services in ... sponsors and clinical research organizations. With dramatic ...
... ARBOR, Mich., April 7, 2011 Adeona Pharmaceuticals, Inc. (AMEX: ... serious central nervous system diseases, announced today that it has ... its common stock at approximately $2.0725 per share to a ... million in gross proceeds. The investor will also receive warrants ...
Cached Medicine Technology:C3i Opens Asia Language Center in Dalian, China 2Adeona to Raise $3.5 Million in Registered Direct Offering 2Adeona to Raise $3.5 Million in Registered Direct Offering 3
(Date:7/30/2014)... The Europe commercial aviation actuation system ... it is expected to reach $1,686.72 million by 2019 ... offers an exclusive range of opportunities and challenges which ... aviation has seen slumps in the past, yet the ... returned to its long-term growth rate of approximately 5 ...
(Date:7/30/2014)... 30, 2014 A marketing services ... technology startups is now available from Modern ... based in the Chicago region. The practice will ... information technology (IT), services, ecommerce, healthcare, private equity ... disciplines critical to startup success include competitive research, ...
(Date:7/30/2014)... Beach, CA (PRWEB) July 30, 2014 ... hired new employees and continues to grow quickly. Chris’ ... Suite 260, Laguna Beach, across the street from Three ... intersection. , Previous to State Farm, Chris had ... Restaurant industry headquartered in Irvine, California, where his responsibilities ...
(Date:7/30/2014)... Recently, Agebc.com, one of the most ... its new line of affordable flower girl dresses ... in several popular styles: sequined ball-gown, scoop neckline, fully ... company’s fresh assortment are: short chiffon dresses with delicate ... of course the classic beautiful colored tulle flower girl ...
(Date:7/30/2014)... teen who died of a caffeine overdose in May ... mass-consumed substance. To help prevent serious health problems that ... reporting progress toward a rapid, at-home test to detect ... and even breast milk. Their report appears in ACS, ... Mani Subramanian and colleagues note that caffeine,s popularity as ...
Breaking Medicine News(10 mins):Health News:Europe Aviation Actuation System Market is Expected to Reach $1,686.72 Million in 2019 - New Report by MicroMarket Monitor 2Health News:Europe Aviation Actuation System Market is Expected to Reach $1,686.72 Million in 2019 - New Report by MicroMarket Monitor 3Health News:Europe Aviation Actuation System Market is Expected to Reach $1,686.72 Million in 2019 - New Report by MicroMarket Monitor 4Health News:Startup Marketing Practice Launched by Modern Marketing Partners 2Health News:State Farm Agent Chris Risi Is Celebrating His Agency's 1st Year Anniversary In September 2Health News:Affordable Flower Girl Dresses Recently Unveiled at Agebc.com 2
... danger, study warns , MONDAY, June 1 (HealthDay News) ... eat enough to cover their energy output face the ... female athletes in the same circumstances, new research suggests. ... place dancers at higher risk for the "cardiovascular ...
... OTTAWA, June 1 /PRNewswire-FirstCall/ - MDS Nordion, a leading ... of,Canada and Atomic Energy of Canada Limited (AECL) to ... the MAPLE,project to address the current shortage of medical ... (NRU) reactor at Chalk River,Ontario - and to avoid ...
... EMERYVILLE, Calif., June 1 Bayer HealthCare Pharmaceuticals, Inc. ... today announced that the companies have begun enrolling patients ... (sorafenib) tablets in patients with non-squamous non-small cell lung ... treatments. , , "Nexavar has proven efficacy in ...
... Expands Veran,s electromagnetic (EM) navigation for oncology procedures. ... Veran Medical Technologies announced today that it has ... property. Veran secured a worldwide license to ... The Navigation division of Medtronic has developed ...
... twenty-somethings who attend or have graduated from private religious ... peers from public schools, according to sociological research published ... Health and Social Behavior . "This research suggests ... of social, financial and health-related factors that can make ...
... International (NYSE: VRX ) announced today that it ... SGP ) for taribavirin in Japan. In ... and release its last right of refusal on taribavirin under ... pursue partnering arrangements for the rest of the world. ...
Cached Medicine News:Health News:MDS Nordion Urges Government of Canada to Complete MAPLE Project to Address Current Medical Isotope Supply Shortage 2Health News:MDS Nordion Urges Government of Canada to Complete MAPLE Project to Address Current Medical Isotope Supply Shortage 3Health News:MDS Nordion Urges Government of Canada to Complete MAPLE Project to Address Current Medical Isotope Supply Shortage 4Health News:MDS Nordion Urges Government of Canada to Complete MAPLE Project to Address Current Medical Isotope Supply Shortage 5Health News:Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non-Small Cell Lung Cancer 2Health News:Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non-Small Cell Lung Cancer 3Health News:Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non-Small Cell Lung Cancer 4Health News:Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non-Small Cell Lung Cancer 5Health News:Veran Medical Technologies Announces Intellectual Property Agreement With Medtronic 2Health News:Religious devotion does not impact abortion decisions of young unwed women 2Health News:Valeant Grants Schering-Plough Exclusive Option in Japan for Taribavirin in Exchange for Release of Last Right of Refusal 2Health News:Valeant Grants Schering-Plough Exclusive Option in Japan for Taribavirin in Exchange for Release of Last Right of Refusal 3
... technology makes BURANE XL a ... array of aesthetic laser applications. ... controllable mode for coagulation, an ... procedures, and in particular a ...
... Test is an in vitro immunoassay intended for ... tumor associated antigen. It is indicated for use ... cancer in conjunction with cystoscopy or when prescribed ... by the FDA for prescription home use in ...
Used for measuring rectal pressure during urodynamic studies. All-silicone construction provides maximum softness and biocompatibility for enhanced patient comfort. Supplied sterile in peel-open pack...
Used for cystometry and urethral pressure profilometry. A loop is employed to enhance catheter retention and stabilization within the bladder. Supplied sterile in peel-open packages. Intended for one...
Medicine Products: